http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0735895-A4

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93d4be1122ac19a1f6b4b45a73b1645f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-12
filingDate 1994-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e47d0a0e14b110866bc8e22e47862e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_076be070274b1f4f23782b0e12bdd36c
publicationDate 2001-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0735895-A4
titleOfInvention PROCEDURE FOR PROPHYLAXIS OR CONTROL OF THE CATARACT
abstract The present invention relates to a method for preventing or controlling pathological changes which occur in association with cataract formation in the mammalian eye by reducing the amount of or inhibiting the action of transforming growth factor-beta(TGFbeta). The invention also relates to the use of inhibitors of TGFbeta to prevent or minimise "aftercataract".
priorityDate 1993-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2250442-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SU-1500254-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S61233622-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9103990-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6433718
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226506884

Total number of triples: 35.